Oncotarget

Research Papers:

Inhibition of coiled coil domain containing protein 69 enhances platinum-induced apoptosis in ovarian cancer cells

Long Cui _, Bo Liang, Yihua Yang, Minhui Zhu, Joseph Kwong, Hongliang Zheng and Chi Chiu Wang

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:101634-101648. https://doi.org/10.18632/oncotarget.21356

Metrics: PDF 786 views  |   HTML 1602 views  |   ?  


Abstract

Long Cui1,2, Bo Liang2, Yihua Yang3, Minhui Zhu1, Joseph Kwong2, Hongliang Zheng1 and Chi Chiu Wang2,4,5

1Department of Otorhinolaryngology-Head and Neck Surgery, Changhai Hospital, Second Military Medical University, Shanghai, People’s Republic of China

2Department of Obstetrics and Gynaecology, Prince of Wales Hospital, The Chinese University of Hong Kong, Shatin, Hong Kong

3Center of Reproductive Medicine, Affiliated Hospital of Guilin Medical College, Guilin, People’s Republic of China

4Reproduction and Development Laboratory, Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, Shatin, Hong Kong

5School of Biomedical Sciences, The Chinese University of Hong Kong, Shatin, Hong Kong

Correspondence to:

Long Cui, email: longcui@link.cuhk.edu.hk

Hongliang Zheng, email: zheng_hl2004@163.com

Chi Chiu Wang, email: ccwang@cuhk.edu.hk

Keywords: cell cycle arrest; chemoresistance; ovarian cancer; apoptosis; p53 acetylation

Received: May 24, 2017    Accepted: August 29, 2017    Published: September 28, 2017

ABSTRACT

Cisplatin is a platinum-based drug that is used for the treatment of human gynecological cancers. However, molecular mechanisms of chemo-resistance in ovarian cancer are poorly understood. The aim of the study is to examine the role of coiled coil domain containing protein 69 (CCDC69) in the underlying mechanism of chemoresistance. Heavy CpG methylation (73.1% and 74.3%) was found in A2780 and A2780cis cells assessing by bisulfite sequencing. Restoration in the expression of CCDC69 was found in A2780 and A2780cis cells after 5-Aza-dC treatment. In fact, the expression levels of CCDC69 were about 3-4 fold higher in cisplatin-resistant A2780cis cells than its parental cisplatin-sensitive A2780 cells. When knockout CCDC69 in cisplatin-resistant A2780cis and SKOV3 cells by CRISPR/Cas9, the CCDC69 knockout cisplatin-resistant A2780cis and CCDC69 knockout SKOV3 cells were also shown increased sensitive to cisplatin treatment. Moreover, treating CCDC69 knockout A2780cis cells with cisplatin, abrogated G1 and G2/M arrest, increased of cleaved caspase 3&8, greater ΔΨm loss and higher levels of Bax were observed. When restoring CCDC69 expression in CCDC69 knockout A2780cis cells by transient transfection, it attenuated sensitivity to cisplatin. By immunoblotting, we found that depletion of CCDC69 increased p53 acetylation at K382 site and Bax mitochondrial redistribution. Additionally, inhibition of c-Myc enhanced cisplatin sensitivities in CCDC69 knockout A2780cis cells, overexpression of c-Myc reduced apoptosis in CCDC69 knockout SKOV3 cells. Our results showed that CCDC69 inhibition might interfere with the effectiveness of combination therapy with platinum drugs.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 21356